東曜藥業(01875.HK)夥華潤醫藥(03320.HK)組腫瘤藥合營
東曜藥業(01875.HK)公佈,於昨日(23日),附屬「曜展」及其員工持股平臺「蘇州華曜員」,與華潤醫藥(03320.HK)旗下「華潤醫藥商貿」,分別出資2,350萬元人民幣(下同)、950萬元及1,700萬元,共同成立合營企業「華曜」,以推行腫瘤藥物商業運營模式變革,及腫瘤藥物市場的創新發展。華曜擬主要從事推廣及銷售創新腫瘤藥物,及向癌症患者及腫瘤醫療專業人士提供專業醫學服務。
華曜爲集團合營企業,其財務業績將使用權益法,於綜合財務報表入賬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.